Genmab A/S, of Copenhagen, Denmark, said worldwide net trade sales of Darzalex (daratumumab), as reported by partner New Brunswick-N.J.-based Johnson & Johnson, were $937 million in the first quarter of 2020, including $463 million in U.S. revenue and $474 million from rest of the world. Genmab will receive royalties on the worldwide net sales of Darzalex under the exclusive worldwide license to Janssen Biotech Inc. to develop, manufacture and commercialize Darzalex. Genmab shares (NASDAQ:GMAB) share rose almost 1% to close at $22.20 on April 14.
Theratechnologies Inc., of Montreal, said it logged $15.7 million in first-quarter net sales, up 4.1% from the same quarter last year. The increase was driven by growing sales of Trogarzo (ibalizumab) for the treatment of multidrug-resistant HIV-1, sales of which climbed 17.4% from the first quarter of 2018. Sales of its tesamorelin-based products for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Egrifta and Egrifta SV, fell slightly in the first quarter of 2019 vs. the first quarter of 2018. The company had a cash position of $34.7 million at Feb. 29, it said. Theratechnologies shares (NASDAQ:THTX) rose 19 cents, or 10.4%, to $2.02 on April 14.